Welcome to our dedicated page for Bioxcel Therapeutics SEC filings (Ticker: BTAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioXcel Therapeutics filings document regulatory, financing, governance, and operating disclosures for a Nasdaq-listed biopharmaceutical company focused on AI-supported drug re-innovation in neuroscience. The company’s Form 8-K reports include IGALMI regulatory updates, business and financial results, and exhibits tied to press releases and material corporate events.
The filing record also covers registered direct offerings, common stock, pre-funded warrants and accompanying warrants, credit agreement amendments, registration rights, unregistered equity issuances, and retention or milestone-based compensation arrangements. These disclosures describe BioXcel’s capital structure, contractual obligations, Nasdaq-listed common stock, and formal updates connected to its approved IGALMI product and BXCL501 development program.
BioXcel Therapeutics reported topline operational and safety observations from its SERENITY At-Home Pivotal Phase 3 trial of BXCL501 for agitation. The company randomized 246 patients and collected data on 2,628 agitation episodes, treating 2,437 episodes in 208 patients; 168 patients (81%) completed the 12-week trial and treated patients averaged 11.7 episodes each. All patients could self-administer the film and there were no drug-related serious adverse events, syncopes, falls, or severe treatment-emergent adverse events reported. Based on episode frequency seen in the trial and external surveys, the company estimates 57 million to 77 million annual agitation episodes in U.S. at-home settings and cites strong patient interest in using BXCL501.
The company is registering the offer and sale of up to $80,000,000 of its common stock under an at-the-market offering program with Canaccord Genuity. This increases the maximum amount it can sell under an existing equity distribution agreement, under which it has already sold $11,635,000 of common stock. As of the date immediately prior to this supplement, the aggregate market value of common stock held by non-affiliates exceeded $75 million, based on 16,009,124 outstanding shares and a closing price of $6.80 per share on August 12, 2025. The stock trades on the Nasdaq Global Market under the symbol “BTAI”, and the last reported sale price on August 15, 2025 was $5.48 per share.
BioXcel Therapeutics, Inc. filed a prospectus supplement for the offer and sale of up to $80,000,000 shares of common stock under its at-the-market program with Canaccord Genuity LLC. This program allows the company to sell common stock from time to time through Canaccord Genuity acting as sales agent. The filing also notes that Honigman LLP issued a legal opinion on the validity of the shares issuable under the Equity Distribution Agreement and the prospectus supplement, and this opinion is included as an exhibit to the report.
BioXcel Therapeutics reported that it received positive pre-sNDA meeting comments from the U.S. FDA for its planned supplemental new drug application (sNDA) for BXCL501 to treat agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting. Based on this written feedback, the company believes its planned regulatory package will be sufficient to support the sNDA submission, which remains on track for the first quarter of 2026.
The pre-sNDA interaction focused on aligning with the FDA on the content and format of the submission, including clinical, nonclinical, and chemistry, manufacturing and controls requirements. BioXcel considers the meeting objectives achieved through the FDA’s written responses and cancelled the previously scheduled in-person meeting, with the preliminary written comments now serving as the official record. Acceptance of the sNDA will still depend on the FDA’s review of the complete filing.
BioXcel Therapeutics, Inc. reported receiving positive preliminary meeting comments from the U.S. Food and Drug Administration (FDA) ahead of a planned pre-supplemental New Drug Application (pre-sNDA) meeting scheduled for August 20, 2025. The company is reviewing this feedback and plans to provide an update next week. The upcoming pre-sNDA meeting is intended to align with the FDA on the proposed format and content of BioXcel’s planned sNDA submission, covering clinical, nonclinical, and chemistry, manufacturing and controls (CMC) requirements.
BioXcel Therapeutics reported continuing commercial sales of IGALMI® while operating at substantial loss and liquidity stress. Cash, cash equivalents and restricted cash were $18.6 million at June 30, 2025, down from $29.9 million at December 31, 2024, and the company recorded a six‑month net loss of $26.4 million. Product revenue was limited at $288 thousand for the six months, reflecting early commercial traction but small sales relative to expenses.
Balance sheet and capital structure show material leverage: total debt was reported net at $108.7 million with long‑term debt of $97.5 million, derivative liabilities of $2.6 million, and an accumulated deficit of $676.6 million. Current assets of $25.2 million compare with current liabilities of $33.4 million, indicating near‑term liquidity pressure. Management disclosed substantial doubt about the company’s ability to continue as a going concern and described Board‑approved reprioritization and cost reductions that have not fully mitigated that doubt.
The company retains access to its OFA Credit Agreement capacity of up to $202.3 million in term loans with $80.0 million of tranches remaining unfunded subject to milestones; financing amendments have altered interest and covenants. The report documents past and planned equity raises and other capital actions but emphasizes dependency on additional capital to fund operations.
BioXcel Therapeutics furnished a press release announcing financial results for the three months ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Form 8-K. The company expressly states the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and therefore is not incorporated by reference into registration statements except as expressly noted.
The report also identifies Exhibit 104 (cover page interactive XBRL tags). The Form itself does not contain the financial line items or tables; readers must consult Exhibit 99.1 for the detailed results and the business commentary.
BioXcel Therapeutics, Inc. disclosed participation by its CEO in a Canaccord fireside chat and detailed compliance with an Oaktree financing covenant tied to a Fifth Amendment to its credit agreement. The covenant required staged capital raises: $7.0M (Raise 1), $18.0M cumulative by March 15, 2025 (Raise 2), and $29.0M cumulative by mid-August 2025 or 30 days after a clinical readout.
The company completed a November 2024 public offering (net ≈ $6.2M), a March 2025 registered direct (net ≈ $13.0M), and an ATM program that sold 5,774,018 shares for net proceeds of ≈ $11.2M. As of August 8, 2025 the company reported ≈ $30.4M in aggregate net proceeds and 13,709,124 shares outstanding, satisfying the Oaktree Financing Covenant. The filing attaches the press release and Inline XBRL cover page as exhibits.
BioXcel Therapeutics disclosed a corporate presentation on its website describing the commercial opportunity for BXCL501 in connection with upcoming SERENITY At-Home Phase 3 study results. The filing states the presentation is attached as Exhibit 99.1 and that the exhibit contains forward-looking statements, which are based on current expectations and subject to limitations disclosed in the exhibit and the company’s other SEC filings.
The report does not present clinical data, financial results, or material transactions; it serves to communicate the company’s commercial case for BXCL501 and to make related forward-looking commentary available to investors.